statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This indicator may be signaling that KROS's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Keros Therapeutics (KROS, $67.05) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2024

Keros Therapeutics, Inc. (NASDAQ:KROS  Free Report)  Equities researchers at William Blair raised their Q1 2024 EPS estimates for shares of Keros Therapeutics in a research report...

Q1 2024 EPS Estimates for Keros Therapeutics, Inc. (NASDAQ:KROS) Lifted by William Blair

In a report released on March 27, Thomas Smith from Leerink Partners reiterated a Buy rating on Keros Therapeutics (KROS Research Report), with a...

Buy Rating Affirmed for Keros Therapeutics Amid FDA Approval Landscape and Market Opportunity for KER-012

This indicator may be signaling KROS's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

Keros Therapeutics (KROS, $66.2) entered Uptrend as Momentum indicator ascends above 0 level on Mar 28, 2024

Keros Therapeutics (KROS, $66.99) entered Uptrend as Momentum indicator ascends above 0 level on Mar 20, 2024

LEXINGTON, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ( Keros ) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...

Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes

Keros Therapeutics (KROS, $67.54) entered Downtrend as Momentum indicator drops below 0 level on Mar 12, 2024

This is a signal that KROS's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Keros Therapeutics (KROS, $66.31) RSI Indicator left the overbought zone on March 11, 2024

Keros Therapeutics (KROS, $70.55) RSI Indicator left the overbought zone on March 08, 2024

Keros Therapeutics, Inc. (NASDAQ:KROS  Free Report)  Equities researchers at William Blair increased their FY2024 earnings estimates for Keros Therapeutics in a research note issued...

FY2024 EPS Estimates for Keros Therapeutics, Inc. (NASDAQ:KROS) Raised by Analyst

Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.

Watchers	203
52-Wk Low	$27.02
52-Wk High	$73.00

Volume	271,195.00
52-Wk High	$73.00
52-Wk Low	$27.02

Period	Estimated	Reported	Surprise	Result
Q2'24	-$1.25	--	--	N/A
Q1'24	-$1.33	-$1.21	9.25%	BEAT
Q4'23	-$1.37	-$1.34	2.49%	BEAT
Q3'23	-$1.35	-$1.33	1.34%	BEAT
Q2'23	-$1.34	-$1.27	5.15%	BEAT

KROS Keros Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals